Intensity Therapeutics, Inc. (INTS)

Intensity Therapeutics will go public soon, but the exact IPO date is still unknown.
IPO Price Range
$4.00 - $5.00
Shares Offered
2,222,223
Deal Size
$10.00M

Company Description

Intensity Therapeutics, Inc. is a clinical stage biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction leading to anti-cancer immune activation.

Our new approach involves the direct injection into tumors of a unique product created from our DfuseRx℠ discovery platform. Our platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules.

Amphiphilic molecules have two distinct components: one part is soluble in water and the other is soluble in fat or oils. When an amphiphilic compound is mixed with therapeutic agents, such as chemotherapies, the agents also become soluble in both fat and water.

Our lead product candidate, INT230-6, consists of two proven anti-cancer cytotoxic agents, cisplatin and vinblastine sulfate, mixed with the amphiphilic molecule (SHAO) — all in one vial.

In 2017, we initiated a Phase 1/2 dose escalation study using INT230-6 under an investigational new drug application. The study, IT-01, is exploring the safety and efficacy of INT230-6 in patients with refractory or metastatic cancers.

We are currently conducting the Phase 2 portion of the trial, which consists of several different expansion cohorts. We are also evaluating INT230-6 in a Phase 2 study (the INVINCIBLE study) in Canada as a treatment prior to surgery in early stage breast cancer.

Intensity Therapeutics, Inc.
Country United States
Founded 2012
Industry Biotechnology
Sector Health Care
Employees 8
CEO Lewis H. Bender

Contact Details

Address:
61 Wilton Road, 3rd Floor
Westport, CT 06880
United States
Phone (203) 221-7381
Website intensitytherapeutics.com

Stock Details

Ticker Symbol INTS
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency US Dollars
CIK Code 1567264

Key Executives

Name Position
Lewis H. Bender President, Chief Executive Officer and Chairman of the Board
Dr. Ian B. Walters Vice President and Chief Medical Officer
Gregory Wade Chief Financial Officer
John Wesolowski Principal Accounting Officer and Controller
Rebecca Drain Vice President, Regulatory Affairs and Quality
Dr. Declan Doogan Director
Dr. Emer Leahy Director
Dr. Mark A. Goldberg Director

Latest SEC Filings

Date Type Title
Oct 3, 2022 S-1/A [Amend] General form for registration of securities under the Securities Act of 1933
Sep 20, 2022 FWP Free Writing Prospectus
Sep 20, 2022 S-1/A [Amend] General form for registration of securities under the Securities Act of 1933
May 16, 2022 S-1/A [Amend] General form for registration of securities under the Securities Act of 1933
Apr 20, 2022 FWP Free Writing Prospectus
Apr 20, 2022 S-1/A [Amend] General form for registration of securities under the Securities Act of 1933
Jan 7, 2022 FWP Free Writing Prospectus
Jan 7, 2022 S-1/A [Amend] General form for registration of securities under the Securities Act of 1933
Dec 16, 2021 FWP Free Writing Prospectus
Dec 9, 2021 S-1/A [Amend] General form for registration of securities under the Securities Act of 1933